Naloxone Market Size, Trends and Insights By Type (Injectable, Intranasal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Opioid Overdose Reversal, Chronic Pain Management), By End-User (Hospitals, Ambulatory Surgical Centers, Rehabilitation Centers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2023–2032


Report Code: CMI35500

Published Date: December 2023

Pages: 320+

Category: Pharmaceuticals

Report Snapshot

CAGR: 11%
1,010.6M
2022
1,119.9M
2023
2,470.2M
2032

Source: CMI

Study Period: 2023-2032
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Adapt Pharma Inc.
  • Mylan N.V.
  • Hospira Inc. (Pfizer Inc.)
  • Kaleo Inc.
  • Amphastar Pharmaceuticals Inc.
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

Global Naloxone Market is expected to witness substantial growth from 2023 to 2032, driven by factors such as the rising prevalence of opioid overdoses, increased awareness of naloxone as a life-saving intervention, and ongoing efforts to address the opioid epidemic.

The market is projected to achieve a Compound Annual Growth Rate (CAGR) of approximately 11% during this period. In 2023, the market is estimated to be valued at USD 1,119.9 Million, and it is expected to reach USD 2,470.2 Million by 2032.

Naloxone, an opioid receptor antagonist, plays a crucial role in reversing the effects of opioid overdoses and is widely utilized in emergency settings.

Factors Influencing Market Growth:

Injectable Naloxone

  • Description: Injectable naloxone is administered via intramuscular or intravenous routes and is a common form used in emergency medical situations.
  • Impact on Growth: The ease of administration and rapid reversal of opioid effects make injectable naloxone a preferred choice for first responders, healthcare professionals, and bystanders in overdose emergencies.

Intranasal Naloxone

  • Description: Intranasal naloxone is delivered through the nasal mucosa, providing a non-invasive and user-friendly alternative for opioid overdose reversal.
  • Impact on Growth: The accessibility and simplicity of intranasal administration contribute to its adoption in community-based settings, where immediate response to opioid overdoses is crucial.

Hospital Pharmacies

  • Description: Hospital pharmacies play a key role in dispensing naloxone to healthcare institutions and individuals.
  • Impact on Growth: The direct availability of naloxone in hospital pharmacies ensures quick access for medical professionals and contributes to the inclusion of naloxone in emergency medical protocols.

Retail Pharmacies

  • Description: Retail pharmacies offer naloxone to the general public, enabling individuals to obtain the medication for personal or community use.
  • Impact on Growth: The accessibility of naloxone in retail settings supports community-level distribution and enhances public access to this life-saving intervention.

Online Pharmacies

  • Description: Online pharmacies provide a convenient platform for individuals to purchase naloxone and have it delivered to their doorstep.
  • Impact on Growth: The increasing prevalence of online pharmacies expands the reach of naloxone to a broader population, especially in regions with limited physical access to healthcare facilities.

Opioid Overdose Reversal

  • Description: Naloxone is primarily used for the rapid reversal of opioid overdoses, preventing fatal outcomes by restoring normal respiratory function.
  • Impact on Growth: The growing awareness of naloxone as a critical tool in opioid harm reduction strategies contributes to its increased use for overdose reversal in various settings.

Chronic Pain Management

  • Description: Naloxone is explored in combination formulations with opioids to deter misuse and reduce the risk of opioid-related side effects in chronic pain management.
  • Impact on Growth: The integration of naloxone in pain management approaches aligns with efforts to address opioid-related complications and enhance patient safety.

Hospitals

  • Description: Hospitals serve as key institutions for naloxone administration in emergency departments and other critical care settings.
  • Impact on Growth: The incorporation of naloxone into hospital protocols enhances the preparedness to manage opioid-related emergencies and contributes to patient safety initiatives.

Ambulatory Surgical Centers

  • Description: Ambulatory surgical centers utilize naloxone to address opioid-related complications during outpatient procedures.
  • Impact on Growth: The inclusion of naloxone in ambulatory settings supports patient safety and aligns with the broader efforts to mitigate the risks associated with opioid use in various medical settings.

Rehabilitation Centers

  • Description: Rehabilitation centers incorporate naloxone as part of their harm reduction strategies to address opioid overdoses among individuals undergoing treatment.
  • Impact on Growth: The use of naloxone in rehabilitation centers contributes to creating safer environments for individuals recovering from opioid use disorders.

Global Naloxone Market – Mergers and Acquisitions

Adapt Pharma’s Acquisition by Emergent BioSolutions

  • Details: Emergent BioSolutions acquired Adapt Pharma, the manufacturer of Narcan (intranasal naloxone), to strengthen its position in the opioid overdose reversal market.
  • Impact: The acquisition enhanced Emergent BioSolutions’ portfolio, combining Adapt Pharma’s expertise in naloxone formulations with Emergent’s capabilities in biodefense and public health solutions.

Mylan N.V. and Pfizer Inc.’s Merger

  • Details: Mylan N.V. merged with Pfizer Inc.’s Upjohn division to form Viatris Inc. The merger included Mylan’s portfolio of generic and specialty pharmaceuticals, which may include naloxone products.
  • Impact: The merger created a global pharmaceutical company with a diverse product portfolio, potentially influencing the distribution and accessibility of naloxone.

Kaleo, Inc.’s Acquisition of Adapt Pharma

  • Details: Kaleo, Inc. acquired Adapt Pharma, consolidating two companies focused on naloxone products. Adapt Pharma was known for Narcan, while Kaleo developed the auto-injector device Evzio.
  • Impact: The acquisition allowed Kaleo to expand its portfolio and market presence in the naloxone delivery devices segment.

BD’s Acquisition of C.R. Bard

  • Details: Becton, Dickinson and Company (BD) acquired C.R. Bard, a medical technology company, which broadened BD’s medical device offerings. This may impact the manufacturing and distribution of naloxone-related medical devices.
  • Impact: The acquisition strengthened BD’s position in the healthcare industry, potentially influencing the development and distribution of medical devices related to naloxone administration.

Indivior PLC’s Acquisition of Aquestive Therapeutics

  • Details: Indivior PLC acquired Aquestive Therapeutics, a pharmaceutical company known for its film formulations of medications, including Suboxone (buprenorphine/naloxone).
  • Impact: The acquisition expanded Indivior’s product portfolio, potentially influencing the market dynamics of medications combining buprenorphine and naloxone for opioid use disorder.

UCB Pharma Limited’s Collaboration with Naloxone Exchange

  • Details: UCB Pharma Limited collaborated with Naloxone Exchange, a platform focused on naloxone distribution and education, to enhance community access to naloxone.
  • Impact: The collaboration aimed to improve naloxone availability and increase awareness, emphasizing the role of partnerships in addressing opioid overdoses at the community level.

Opiant Pharmaceuticals’ Acquisition of Adapt Pharma

  • Details: Opiant Pharmaceuticals, a company specializing in addiction and overdose treatments, acquired Adapt Pharma, the maker of Narcan, to strengthen its position in the opioid overdose market.
  • Impact: The acquisition allowed Opiant Pharmaceuticals to expand its portfolio of addiction treatment options, including naloxone formulations.

Novartis AG’s Collaboration with Harvard University

  • Details: Novartis AG collaborated with Harvard University to develop advanced formulations of naloxone for improved efficacy and ease of use.
  • Impact: The collaboration aimed to leverage scientific expertise to enhance naloxone formulations, addressing challenges related to administration and effectiveness in opioid overdose situations.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Naloxone Market Enbrel Market Vyndaqel Market
CAGR 11% (Approx) CAGR 3.7% (Approx) CAGR 15.8% (Approx)
USD 2,470.2 Million by 2032 USD 23.2 Billion by 2032 USD 9.2 Billion by 2032

Challenges Impacting the Naloxone Market:

Training and Education

  • Challenge: Ensuring proper training and education for individuals, including first responders and community members, on naloxone administration.
  • Impact: Adequate training is crucial for the effective use of naloxone, and addressing this challenge is essential for optimizing the impact of naloxone distribution programs.

Accessibility and Affordability

  • Challenge: Ensuring widespread accessibility and affordability of naloxone to individuals across various socio-economic backgrounds.
  • Impact: Overcoming barriers related to cost and access is critical to maximizing the reach of naloxone and ensuring its availability to those at risk of opioid overdose.

Stigma and Public Perception

  • Challenge: Overcoming the stigma associated with opioid use and naloxone administration, which may hinder public acceptance and engagement.
  • Impact: Efforts to destigmatize naloxone use are essential to encourage its adoption and increase community involvement in overdose response initiatives.

Legislative and Regulatory Barriers

  • Challenge: Addressing regulatory complexities and barriers that may hinder the implementation of naloxone distribution programs in certain regions.
  • Impact: Streamlining regulatory processes and advocating for supportive policies are crucial for ensuring the effective deployment of naloxone in diverse settings.

Community Engagement and Awareness

  • Challenge: Promoting community engagement and awareness to enhance the understanding of naloxone’s role in overdose response.
  • Impact: Community involvement is vital for the success of naloxone distribution programs, and addressing this challenge is essential for building a proactive and informed response to opioid overdoses.

Integration with Emergency Services

  • Challenge: Ensuring seamless integration of naloxone use with existing emergency medical services and healthcare systems.
  • Impact: Collaboration between naloxone distributors and emergency services is crucial for optimizing response times and improving outcomes in opioid overdose emergencies.

Research and Development Focus

  • Challenge: Continued research and development to enhance naloxone formulations, delivery methods, and technologies.
  • Impact: Advancements in naloxone technology contribute to improved efficacy, ease of use, and adaptability to diverse settings, supporting its broader adoption and impact.

Data Collection and Reporting

  • Challenge: Establishing robust systems for data collection and reporting related to naloxone administration and opioid overdoses.
  • Impact: Reliable data is essential for evaluating the effectiveness of naloxone distribution programs and guiding future strategies to address opioid-related challenges.

Collaboration with Healthcare Professionals

  • Challenge: Facilitating collaboration between naloxone distributors and healthcare professionals to ensure coordinated care for individuals at risk of opioid overdose.
  • Impact: Coordinated efforts between distributors and healthcare providers contribute to a comprehensive approach to overdose prevention and treatment.

Report Scope

Feature of the Report Details
Market Size in 2023 USD 1,119.9 Million
Projected Market Size in 2032 USD 2,470.2 Million
Market Size in 2022 USD 1,010.6 Million
CAGR Growth Rate 11% CAGR
Base Year 2022
Forecast Period 2023-2032
Key Segment By Type, Distribution Channel, Application, End-User and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Segmentation Analysis of the Naloxone Market:

By Type

Injectable Naloxone

  • Description: Injectable naloxone is administered via intramuscular or intravenous routes and is a common form used in emergency medical situations.
  • Market Impact: The ease of administration and rapid reversal of opioid effects make injectable naloxone a preferred choice for first responders, healthcare professionals, and bystanders in overdose emergencies.

Intranasal Naloxone

  • Description: Intranasal naloxone is delivered through the nasal mucosa, providing a non-invasive and user-friendly alternative for opioid overdose reversal.
  • Market Impact: The accessibility and simplicity of intranasal administration contribute to its adoption in community-based settings, where immediate response to opioid overdoses is crucial.

Global Naloxone Market 2023–2032 (By Million)

www.custommarketinsight.com

By Distribution Channel

Hospital Pharmacies

  • Description: Hospital pharmacies play a key role in dispensing naloxone to healthcare institutions and individuals.
  • Market Impact: The direct availability of naloxone in hospital pharmacies ensures quick access for medical professionals and contributes to the inclusion of naloxone in emergency medical protocols.

Retail Pharmacies

  • Description: Retail pharmacies offer naloxone to the general public, enabling individuals to obtain the medication for personal or community use.
  • Market Impact: The accessibility of naloxone in retail settings supports community-level distribution and enhances public access to this life-saving intervention.

Online Pharmacies

  • Description: Online pharmacies provide a convenient platform for individuals to purchase naloxone and have it delivered to their doorstep.
  • Market Impact: The increasing prevalence of online pharmacies expands the reach of naloxone to a broader population, especially in regions with limited physical access to healthcare facilities.

By Application

Opioid Overdose Reversal

  • Description: Naloxone is primarily used for the rapid reversal of opioid overdoses, preventing fatal outcomes by restoring normal respiratory function.
  • Market Impact: The growing awareness of naloxone as a critical tool in opioid harm reduction strategies contributes to its increased use for overdose reversal in various settings.

Chronic Pain Management

  • Description: Naloxone is explored in combination formulations with opioids to deter misuse and reduce the risk of opioid-related side effects in chronic pain management.
  • Market Impact: The integration of naloxone in pain management approaches aligns with efforts to address opioid-related complications and enhance patient safety.

Global Naloxone Market 2023–2032 (By Type)

www.custommarketinsight.com

By End-User 

Hospitals

  • Description: Hospitals serve as key institutions for naloxone administration in emergency departments and other critical care settings.
  • Market Impact: The incorporation of naloxone into hospital protocols enhances the preparedness to manage opioid-related emergencies and contributes to patient safety initiatives.

Ambulatory Surgical Centers

  • Description: Ambulatory surgical centers utilize naloxone to address opioid-related complications during outpatient procedures.
  • Market Impact: The inclusion of naloxone in ambulatory settings supports patient safety and aligns with the broader efforts to mitigate the risks associated with opioid use in various medical settings.

Rehabilitation Centers

  • Description: Rehabilitation centers incorporate naloxone as part of their harm reduction strategies to address opioid overdoses among individuals undergoing treatment.
  • Market Impact: The use of naloxone in rehabilitation centers contributes to creating safer environments for individuals recovering from opioid use disorders.

By Region

  • North America: North America leads the naloxone market, driven by the opioid epidemic, widespread naloxone distribution programs, and increased awareness of opioid overdose risks.
  • Europe: Europe plays a significant role in the naloxone market, with increased recognition of naloxone’s role in harm reduction and opioid overdose prevention.
  • Asia-Pacific: Asia-Pacific emerges as a key player in the naloxone market, driven by increasing opioid misuse, the recognition of naloxone’s life-saving potential, and the development of responsive healthcare systems.

Global Naloxone Market 2023–2032 (By Application)

www.custommarketinsight.com

List of the prominent players in the Naloxone Market:

  • Adapt Pharma Inc.
  • Mylan N.V.
  • Hospira Inc. (Pfizer Inc.)
  • Kaleo Inc.
  • Amphastar Pharmaceuticals Inc.
  • Pfizer Inc.
  • Kaléo Pharma LLC
  • Indivior PLC
  • Mundipharma International Limited
  • Opiant Pharmaceuticals Inc.
  • UCB Pharma Limited
  • Novartis AG
  • Narcanon International
  • Evzio
  • BD (Becton Dickinson and Company)
  • Others

The Naloxone Market is segmented as follows:

By Type

  • Injectable
  • Intranasal

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Application

  • Opioid Overdose Reversal
  • Chronic Pain Management

By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Rehabilitation Centers

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America

Europe

  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Naloxone Market, (2023 – 2032) (USD Million)
    • 2.2 Global Naloxone Market: snapshot
  • Chapter 3. Global Naloxone Market – Industry Analysis
    • 3.1 Naloxone Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Opioid Crisis Mitigation
      • 3.2.2 Rising Opioid Abuse Cases
      • 3.2.3 Accessibility and Distribution Programs
      • 3.2.4 Legislative Support
      • 3.2.5 Nasal and Auto-Injector Formulations
      • 3.2.6 Combination Therapies
      • 3.2.7 First Responder Training
      • 3.2.8 Pharmacist Dispensation
      • 3.2.9 Telemedicine Integration
      • 3.2.10 Opioid Addiction Treatment Centers
      • 3.2.11 Community Awareness Campaigns
      • 3.2.12 Research into Long-Acting Formulations.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Type
      • 3.7.2 Market Attractiveness Analysis By Distribution Channel
      • 3.7.3 Market Attractiveness Analysis By Application
      • 3.7.4 Market Attractiveness Analysis By End-User
  • Chapter 4. Global Naloxone Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Naloxone Market: Company Market Share, 2022
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, collaboration, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Naloxone Market – Type Analysis
    • 5.1 Global Naloxone Market Overview: By Type
      • 5.1.1 Global Naloxone Market Share, By Type, 2022 and 2032
    • 5.2 Injectable
      • 5.2.1 Global Naloxone Market by Injectable, 2023 – 2032 (USD Million)
    • 5.3 Intranasal
      • 5.3.1 Global Naloxone Market by Intranasal, 2023 – 2032 (USD Million)
  • Chapter 6. Global Naloxone Market – Distribution Channel Analysis
    • 6.1 Global Naloxone Market Overview: By Distribution Channel
      • 6.1.1 Global Naloxone Market Share, By Distribution Channel, 2022 and 2032
    • 6.2 Hospital Pharmacies
      • 6.2.1 Global Naloxone Market by Hospital Pharmacies, 2023 – 2032 (USD Million)
    • 6.3 Retail Pharmacies
      • 6.3.1 Global Naloxone Market by Retail Pharmacies, 2023 – 2032 (USD Million)
    • 6.4 Online Pharmacies
      • 6.4.1 Global Naloxone Market by Online Pharmacies, 2023 – 2032 (USD Million)
  • Chapter 7. Global Naloxone Market – Application Analysis
    • 7.1 Global Naloxone Market Overview: By Application
      • 7.1.1 Global Naloxone Market Share, By Application, 2022 and 2032
    • 7.2 Opioid Overdose Reversal
      • 7.2.1 Global Naloxone Market by Opioid Overdose Reversal, 2023 – 2032 (USD Million)
    • 7.3 Chronic Pain Management
      • 7.3.1 Global Naloxone Market by Chronic Pain Management, 2023 – 2032 (USD Million)
  • Chapter 8. Global Naloxone Market – End-User Analysis
    • 8.1 Global Naloxone Market Overview: By End-User
      • 8.1.1 Global Naloxone Market Share, By End-User, 2022 and 2032
    • 8.2 Hospitals
      • 8.2.1 Global Naloxone Market by Hospitals, 2023 – 2032 (USD Million)
    • 8.3 Ambulatory Surgical Centers
      • 8.3.1 Global Naloxone Market by Ambulatory Surgical Centers, 2023 – 2032 (USD Million)
    • 8.4 Rehabilitation Centers
      • 8.4.1 Global Naloxone Market by Rehabilitation Centers, 2023 – 2032 (USD Million)
  • Chapter 9. Naloxone Market – Regional Analysis
    • 9.1 Global Naloxone Market Regional Overview
    • 9.2 Global Naloxone Market Share, by Region, 2022 & 2032 (USD Million)
    • 9.3. North America
      • 9.3.1 North America Naloxone Market, 2023 – 2032 (USD Million)
        • 9.3.1.1 North America Naloxone Market, by Country, 2023 – 2032 (USD Million)
    • 9.4 North America Naloxone Market, by Type, 2023 – 2032
      • 9.4.1 North America Naloxone Market, by Type, 2023 – 2032 (USD Million)
    • 9.5 North America Naloxone Market, by Distribution Channel, 2023 – 2032
      • 9.5.1 North America Naloxone Market, by Distribution Channel, 2023 – 2032 (USD Million)
    • 9.6 North America Naloxone Market, by Application, 2023 – 2032
      • 9.6.1 North America Naloxone Market, by Application, 2023 – 2032 (USD Million)
    • 9.7 North America Naloxone Market, by End-User, 2023 – 2032
      • 9.7.1 North America Naloxone Market, by End-User, 2023 – 2032 (USD Million)
    • 9.8. Europe
      • 9.8.1 Europe Naloxone Market, 2023 – 2032 (USD Million)
        • 9.8.1.1 Europe Naloxone Market, by Country, 2023 – 2032 (USD Million)
    • 9.9 Europe Naloxone Market, by Type, 2023 – 2032
      • 9.9.1 Europe Naloxone Market, by Type, 2023 – 2032 (USD Million)
    • 9.10 Europe Naloxone Market, by Distribution Channel, 2023 – 2032
      • 9.10.1 Europe Naloxone Market, by Distribution Channel, 2023 – 2032 (USD Million)
    • 9.11 Europe Naloxone Market, by Application, 2023 – 2032
      • 9.11.1 Europe Naloxone Market, by Application, 2023 – 2032 (USD Million)
    • 9.12 Europe Naloxone Market, by End-User, 2023 – 2032
      • 9.12.1 Europe Naloxone Market, by End-User, 2023 – 2032 (USD Million)
    • 9.13. Asia Pacific
      • 9.13.1 Asia Pacific Naloxone Market, 2023 – 2032 (USD Million)
        • 9.13.1.1 Asia Pacific Naloxone Market, by Country, 2023 – 2032 (USD Million)
    • 9.14 Asia Pacific Naloxone Market, by Type, 2023 – 2032
      • 9.14.1 Asia Pacific Naloxone Market, by Type, 2023 – 2032 (USD Million)
    • 9.15 Asia Pacific Naloxone Market, by Distribution Channel, 2023 – 2032
      • 9.15.1 Asia Pacific Naloxone Market, by Distribution Channel, 2023 – 2032 (USD Million)
    • 9.16 Asia Pacific Naloxone Market, by Application, 2023 – 2032
      • 9.16.1 Asia Pacific Naloxone Market, by Application, 2023 – 2032 (USD Million)
    • 9.17 Asia Pacific Naloxone Market, by End-User, 2023 – 2032
      • 9.17.1 Asia Pacific Naloxone Market, by End-User, 2023 – 2032 (USD Million)
    • 9.18. Latin America
      • 9.18.1 Latin America Naloxone Market, 2023 – 2032 (USD Million)
        • 9.18.1.1 Latin America Naloxone Market, by Country, 2023 – 2032 (USD Million)
    • 9.19 Latin America Naloxone Market, by Type, 2023 – 2032
      • 9.19.1 Latin America Naloxone Market, by Type, 2023 – 2032 (USD Million)
    • 9.20 Latin America Naloxone Market, by Distribution Channel, 2023 – 2032
      • 9.20.1 Latin America Naloxone Market, by Distribution Channel, 2023 – 2032 (USD Million)
    • 9.21 Latin America Naloxone Market, by Application, 2023 – 2032
      • 9.21.1 Latin America Naloxone Market, by Application, 2023 – 2032 (USD Million)
    • 9.22 Latin America Naloxone Market, by End-User, 2023 – 2032
      • 9.22.1 Latin America Naloxone Market, by End-User, 2023 – 2032 (USD Million)
    • 9.23. The Middle East and Africa
      • 9.23.1 The Middle-East and Africa Naloxone Market, 2023 – 2032 (USD Million)
        • 9.23.1.1 The Middle-East and Africa Naloxone Market, by Country, 2023 – 2032 (USD Million)
    • 9.24 The Middle-East and Africa Naloxone Market, by Type, 2023 – 2032
      • 9.24.1 The Middle-East and Africa Naloxone Market, by Type, 2023 – 2032 (USD Million)
    • 9.25 The Middle-East and Africa Naloxone Market, by Distribution Channel, 2023 – 2032
      • 9.25.1 The Middle-East and Africa Naloxone Market, by Distribution Channel, 2023 – 2032 (USD Million)
    • 9.26 The Middle-East and Africa Naloxone Market, by Application, 2023 – 2032
      • 9.26.1 The Middle-East and Africa Naloxone Market, by Application, 2023 – 2032 (USD Million)
    • 9.27 The Middle-East and Africa Naloxone Market, by End-User, 2023 – 2032
      • 9.27.1 The Middle-East and Africa Naloxone Market, by End-User, 2023 – 2032 (USD Million)
  • Chapter 10. Company Profiles
    • 10.1 Adapt Pharma Inc.
      • 10.1.1 Overview
      • 10.1.2 Financials
      • 10.1.3 Product Portfolio
      • 10.1.4 Business Strategy
      • 10.1.5 Recent Developments
    • 10.2 Mylan N.V.
      • 10.2.1 Overview
      • 10.2.2 Financials
      • 10.2.3 Product Portfolio
      • 10.2.4 Business Strategy
      • 10.2.5 Recent Developments
    • 10.3 Hospira Inc. (Pfizer Inc.)
      • 10.3.1 Overview
      • 10.3.2 Financials
      • 10.3.3 Product Portfolio
      • 10.3.4 Business Strategy
      • 10.3.5 Recent Developments
    • 10.4 Kaleo Inc.
      • 10.4.1 Overview
      • 10.4.2 Financials
      • 10.4.3 Product Portfolio
      • 10.4.4 Business Strategy
      • 10.4.5 Recent Developments
    • 10.5 Amphastar Pharmaceuticals Inc.
      • 10.5.1 Overview
      • 10.5.2 Financials
      • 10.5.3 Product Portfolio
      • 10.5.4 Business Strategy
      • 10.5.5 Recent Developments
    • 10.6 Pfizer Inc.
      • 10.6.1 Overview
      • 10.6.2 Financials
      • 10.6.3 Product Portfolio
      • 10.6.4 Business Strategy
      • 10.6.5 Recent Developments
    • 10.7 Kaléo Pharma LLC
      • 10.7.1 Overview
      • 10.7.2 Financials
      • 10.7.3 Product Portfolio
      • 10.7.4 Business Strategy
      • 10.7.5 Recent Developments
    • 10.8 Indivior PLC
      • 10.8.1 Overview
      • 10.8.2 Financials
      • 10.8.3 Product Portfolio
      • 10.8.4 Business Strategy
      • 10.8.5 Recent Developments
    • 10.9 Mundipharma International Limited
      • 10.9.1 Overview
      • 10.9.2 Financials
      • 10.9.3 Product Portfolio
      • 10.9.4 Business Strategy
      • 10.9.5 Recent Developments
    • 10.10 Opiant Pharmaceuticals Inc.
      • 10.10.1 Overview
      • 10.10.2 Financials
      • 10.10.3 Product Portfolio
      • 10.10.4 Business Strategy
      • 10.10.5 Recent Developments
    • 10.11 UCB Pharma Limited
      • 10.11.1 Overview
      • 10.11.2 Financials
      • 10.11.3 Product Portfolio
      • 10.11.4 Business Strategy
      • 10.11.5 Recent Developments
    • 10.12 Novartis AG
      • 10.12.1 Overview
      • 10.12.2 Financials
      • 10.12.3 Product Portfolio
      • 10.12.4 Business Strategy
      • 10.12.5 Recent Developments
    • 10.13 Narcanon International
      • 10.13.1 Overview
      • 10.13.2 Financials
      • 10.13.3 Product Portfolio
      • 10.13.4 Business Strategy
      • 10.13.5 Recent Developments
    • 10.14 Evzio
      • 10.14.1 Overview
      • 10.14.2 Financials
      • 10.14.3 Product Portfolio
      • 10.14.4 Business Strategy
      • 10.14.5 Recent Developments
    • 10.15 BD (Becton Dickinson and Company)
      • 10.15.1 Overview
      • 10.15.2 Financials
      • 10.15.3 Product Portfolio
      • 10.15.4 Business Strategy
      • 10.15.5 Recent Developments
    • 10.16 Others.
      • 10.16.1 Overview
      • 10.16.2 Financials
      • 10.16.3 Product Portfolio
      • 10.16.4 Business Strategy
      • 10.16.5 Recent Developments
List Of Figures

Figures No 1 to 28

List Of Tables

Tables No 1 to 102

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2030

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2030
  • Market revenue estimates and forecasts up to 2030, by technology
  • Market revenue estimates and forecasts up to 2030, by application
  • Market revenue estimates and forecasts up to 2030, by type
  • Market revenue estimates and forecasts up to 2030, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Adapt Pharma Inc.
  • Mylan N.V.
  • Hospira Inc. (Pfizer Inc.)
  • Kaleo Inc.
  • Amphastar Pharmaceuticals Inc.
  • Pfizer Inc.
  • Kaléo Pharma LLC
  • Indivior PLC
  • Mundipharma International Limited
  • Opiant Pharmaceuticals Inc.
  • UCB Pharma Limited
  • Novartis AG
  • Narcanon International
  • Evzio
  • BD (Becton Dickinson and Company)
  • Others

FAQs

The key factors driving the Market are Opioid Crisis Mitigation, Rising Opioid Abuse Cases, Accessibility and Distribution Programs, Legislative Support, Nasal and Auto-Injector Formulations, Combination Therapies, First Responder Training, Pharmacist Dispensation, Telemedicine Integration, Opioid Addiction Treatment Centers, Community Awareness Campaigns And Research into Long-Acting Formulations.

The “Injectable” category dominated the market in 2022.

The key players in the market are Adapt Pharma Inc., Mylan N.V., Hospira Inc. (Pfizer Inc.), Kaleo Inc., Amphastar Pharmaceuticals Inc., Pfizer Inc., Kaléo Pharma LLC, Indivior PLC, Mundipharma International Limited, Opiant Pharmaceuticals Inc., UCB Pharma Limited, Novartis AG, Narcanon International, Evzio, BD (Becton Dickinson and Company), Others.

“North America” had the largest share in the Naloxone Market.

The global market is projected to grow at a CAGR of 11% during the forecast period, 2023-2032.

The Naloxone Market size was valued at USD 1,119.9 Million in 2023.

PURCHASE OPTIONS

$

3490


$

4490


$

5490


$

1950


powerbi pdf
$

6200

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • PDF, Excel, Power Point and Power BI.
  • Every Year Free Update ( Apr – Apr)
  • Personalized market brief by author
  • Can be accessible by unlimited users.
  • Free 50% or 90 hours of customization.
  • Up to 50 Company Profiles
  • Free post-sale service assistance with guarantee
  • 40% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account team.
  • Service guarantee available.

Want to customize this report?
100% FREE CUSTOMIZATION!